本帖最后由 老马 于 2012-1-13 21:20 编辑
3 n+ a" P! X2 D0 W# W$ l
: F3 R+ a2 V7 ~4 N2 K爱必妥和阿瓦斯丁的比较
9 l) K0 V1 X$ r: i" H" S
7 v5 @& x6 j$ D& h3 E$ }4 ghttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/% I5 h" ?: m: Y5 e* G
7 m, v6 w, L- q- a7 U7 i
" e) z9 m$ D3 M" j% }& X. o1 l
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
3 K* y9 k; |( N# u+ S- |==================================================
% f( m, U# p/ v0 N+ C9 `Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)5 w }. O( r/ H+ Q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 b z/ i: W) w6 r2 d) IResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
! N* K8 A: K' F0 H5 S/ q# V) C
|